Santhera Pharmaceuticals Holding AG (XSWX:SANN) Cash Flow from Investing: CHF-0.12 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:SANN Santhera Pharmaceuticals Holding AG XSWX:SANN
38 GF Score
Price CHF16.64
GF Value CHF23.86
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG Cash Flow from Investing?

Santhera Pharmaceuticals Holding AG XSWX:SANN +0.73% 38 Cash Flow from Investing is CHF-0.12 Mil as of Dec. 2025. GuruFocus rates XSWX:SANN with a GF Score™ of 38/100 and a GF Value™ of CHF23.86 (Possible Value Trap). The stock has 7 warning signs investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Dec. 2025, Santhera Pharmaceuticals Holding AG spent CHF-0.02 Mil on purchasing property, plant, equipment. It gained CHF0.00 Mil from selling property, plant, and equipment. It spent CHF0.00 Mil on purchasing business. It gained CHF0.00 Mil from selling business. It spent CHF0.00 Mil on purchasing investments. It gained CHF0.00 Mil from selling investments. It paid CHF0.00Mil for net Intangibles purchase and sale. And it paid CHF0.07 Mil for other investing activities. In all, Santhera Pharmaceuticals Holding AG spent CHF0.05 Mil on investment activities in financial market and operating subsidiaries for the six months ended in Dec. 2025.


Santhera Pharmaceuticals Holding AG  (XSWX:SANN) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Santhera Pharmaceuticals Holding AG's purchase of property, plant, equipment for the six months ended in Dec. 2025 was CHF0.02 Mil. It means Santhera Pharmaceuticals Holding AG spent CHF-0.02 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Santhera Pharmaceuticals Holding AG's sale of property, plant, equipment for the six months ended in Dec. 2025 was CHF0.00 Mil. It means Santhera Pharmaceuticals Holding AG gained CHF0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Santhera Pharmaceuticals Holding AG's purchase of business for the six months ended in Dec. 2025 was CHF0.00 Mil. It means Santhera Pharmaceuticals Holding AG spent CHF0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Santhera Pharmaceuticals Holding AG's sale of business for the six months ended in Dec. 2025 was CHF0.00 Mil. It means Santhera Pharmaceuticals Holding AG gained CHF0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Santhera Pharmaceuticals Holding AG's purchase of investment for the six months ended in Dec. 2025 was CHF0.00 Mil. It means Santhera Pharmaceuticals Holding AG spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Santhera Pharmaceuticals Holding AG's sale of investment for the six months ended in Dec. 2025 was CHF0.00 Mil. It means Santhera Pharmaceuticals Holding AG gained CHF0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Santhera Pharmaceuticals Holding AG's net Intangibles purchase and sale for the six months ended in Dec. 2025 was CHF0.00 Mil. It means Santhera Pharmaceuticals Holding AG paid CHF0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Santhera Pharmaceuticals Holding AG's cash from discontinued investing activities for the six months ended in Dec. 2025 was 0.00 Mil. It means Santhera Pharmaceuticals Holding AG paid CHF0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Santhera Pharmaceuticals Holding AG's cash from other investing activities for the six months ended in Dec. 2025 was CHF-0.07 Mil. It means Santhera Pharmaceuticals Holding AG paid CHF0.07 Mil for other investing activities.


Santhera Pharmaceuticals Holding AG Cash Flow from Investing Related Terms


Santhera Pharmaceuticals Holding AG Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for Santhera Pharmaceuticals Holding AG's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG Cash Flow from Investing Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 -3.93 -18.04 -0.06 -0.12

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.73 0.01 -0.07 -0.07 -0.05
XSWX:SANN
38GF Score
Santhera Pharmaceuticals Holding AG XSWX:SANN
Cash Flow from Investing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santhera Pharmaceuticals Holding AG Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Santhera Pharmaceuticals Holding AG's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:

Santhera Pharmaceuticals Holding AG's Cash Flow from Investing for the quarter that ended in Dec. 2025 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of CHF-0.12 Mil mean?
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a Cash Flow from Investing of CHF-0.12 Mil as of Dec. 2025. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Santhera Pharmaceuticals Holding AG and its competitors.
Is Santhera Pharmaceuticals Holding AG's Cash Flow from Investing too high?
Santhera Pharmaceuticals Holding AG's current Cash Flow from Investing is CHF-0.12 Mil. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Cash Flow from Investing compare to VRTX and REGN?
Santhera Pharmaceuticals Holding AG's Cash Flow from Investing of CHF-0.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Biotechnology company?
A good Cash Flow from Investing depends on the Biotechnology industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Santhera Pharmaceuticals Holding AG and its competitors. Santhera Pharmaceuticals Holding AG's current Cash Flow from Investing is CHF-0.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.86, compared to a current price of CHF16.64 — trading 30.3% below its estimated fair value. The current Cash Flow from Investing is CHF-0.12 Mil. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current Cash Flow from Investing is CHF-0.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of CHF16.64 is trading 30.3% below its estimated GF Value™ of CHF23.86. GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.

Key valuation signals for XSWX:SANN:

  • Cash Flow from Investing: CHF-0.12 Mil
  • GF Value™: CHF23.86 vs. price of CHF16.64 (30.3% below fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
38GF Score

Get the complete analysis for XSWX:SANN

Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF16.64
Price
CHF23.86
GF Value